Viktor KoÄka

List of Publications by Year
in descending order

57	2,990	471509 17	182427 51
papers	citations	h-index	g-index

58	58	58	3339
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. New England Journal of Medicine, 2013, 368, 1303-1313.	27.0	695
2	Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine, 2009, 361, 2330-2341.	27.0	560
3	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. New England Journal of Medicine, 2015, 372, 1389-1398.	27.0	536
4	Heart Failure With Preserved Ejection Fraction in Outpatients With Unexplained Dyspnea. Journal of the American College of Cardiology, 2010, 55, 1701-1710.	2.8	154
5	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent inÂST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. JACC: Cardiovascular Interventions, 2015, 8, 189-197.	2.9	145
6	Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. European Heart Journal, 2008, 29, 1495-1503.	2.2	132
7	Predictors of Improvement of Unrepaired Moderate Ischemic Mitral Regurgitation in Patients Undergoing Elective Isolated Coronary Artery Bypass Graft Surgery. Circulation, 2009, 120, 1474-1481.	1.6	122
8	Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. European Heart Journal, 2014, 35, 787-794.	2.2	120
9	Culprit lesion thrombus burden after manual thrombectomy or percutaneous coronary intervention-alone in ST-segment elevation myocardial infarction: the optical coherence tomography sub-study of the TOTAL (ThrOmbecTomy versus PCI ALone) trial. European Heart Journal, 2015, 36, 1892-1900.	2.2	60
10	Ibutilide-Induced Cardioversion of Atrial Fibrillation During Pregnancy. Journal of Cardiovascular Electrophysiology, 2007, 18, 545-547.	1.7	49
11	Cangrelor With and Without GlycoproteinÂIIb/IIIa Inhibitors inÂPatientsÂUndergoing PercutaneousÂCoronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	2.8	47
12	Feasibility and repeatability of optical coherence tomography measurements of pre-stent thrombus burden in patients with STEMI treated with primary PCI. European Heart Journal Cardiovascular Imaging, 2015, 16, 96-107.	1.2	31
13	Optimal Fluoroscopic Projections of Coronary Ostia and Bifurcations Defined by Computed Tomographic Coronary Angiography. JACC: Cardiovascular Interventions, 2020, 13, 2560-2570.	2.9	28
14	Cardiac resynchronization therapy for the causal treatment of heart failure with preserved ejection fraction: insight from a pressureâ€“volume loop analysis. European Journal of Heart Failure, 2010, 12, 634-636.	7.1	22
15	Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 131-140.	3.0	21
16	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. International Journal of Cardiology, 2016, 214, 483-484.	1.7	20
17	Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update. EuroIntervention, 2016, 12, 23-29.	3.2	18
18	High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. Journal of Thrombosis and Thrombolysis, 2012, 33, 349-354.	2.1	17

#	Article	IF	Citations
19	Cardiac resynchronization therapy implantation following transcatheter aortic valve implantation. Europace, 2011, 13, 290-291.	1.7	15
20	Pharmacodynamic Effect of Clopidogrel in Patients Undergoing Transcatheter Aortic Valve Implantation. BioMed Research International, 2013, 2013, 1-3.	1.9	14
21	Relationship between TRAIL and Left Ventricular Ejection Fraction in Patients with ST-Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. BioMed Research International, 2018, 2018, 1-8.	1.9	12
22	Takotsubo Cardiomyopathy: One More Angiographic Evidence of Microvascular Dysfunction. BioMed Research International, 2018, 2018, 1-6.	1.9	11
23	Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic. Journal of Clinical Medicine, 2021, 10, 24.	2.4	11
24	Successful treatment of massive pulmonary embolism with prolonged catheter-directed thrombolysis. Heart and Vessels, 2006, 21, 124-126.	1.2	10
25	One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, e002933.	3.9	10
26	ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases. European Heart Journal, 2013, 34, 2073-2073.	2.2	9
27	Transcatheter aortic valve implantation: long-term clinical outcome and valve durability. Expert Review of Medical Devices, 2015, 12, 529-535.	2.8	9
28	Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study. Heart and Vessels, 2016, 31, 841-845.	1.2	9
29	Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study. Cardiovascular Drugs and Therapy, 2022, 36, 1129-1136.	2.6	9
30	Invasive Hemodynamic Assessment of Cardiac Output State after MitraClip Therapy in Nonanaesthetized Patients with Functional Mitral Regurgitation. BioMed Research International, 2016, 2016, 1-7.	1.9	8
31	Degenerative changes and immune response after transcatheter aortic valve implantation. Comparison with surgical aortic valve replacement. Journal of Cardiology, 2017, 69, 483-488.	1.9	8
32	Immuneâ€“inflammatory response after bioresorbable vascular scaffold implantation in patients with acute myocardial infarction with ST elevation in a long-term perspective. Heart and Vessels, 2019, 34, 557-563.	1.2	8
33	Bioresorbable scaffold implantation in STEMI patients: 5Âyears imaging subanalysis of PRAGUE-19 study. Journal of Translational Medicine, 2020, 18, 33.	4.4	8
34	Clopidogrel up-titration versus standard dose in patients with high residual platelet reactivity after percutaneous coronary intervention: A single-center pilot randomised study. International Journal of Cardiology, 2011, 150, 231-232.	1.7	7
35	Potential role of invariant natural killer T cells in outcomes of acute myocardial infarction. International Journal of Cardiology, 2015, 187, 663-665.	1.7	7
36	Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial. Cardiovascular Revascularization Medicine, 2019, 20, 577-582.	0.8	7

#	Article	IF	Citations
37	Absorb bioresorbable stents for the treatment of coronary artery disease. Expert Review of Medical Devices, 2015, 12, 545-557.	2.8	6
38	Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2013, 36, 1-6.	2.1	5
39	Long-term follow-up in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. European Heart Journal Supplements, 2022, 24, B16-B22.	0.1	5
40	Five year two center retrospective analysis of patients with toxic digoxin serum concentration. International Journal of Cardiology, 2011, 146, 447-448.	1.7	4
41	Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients â€" Results from PRAGUE-19 study. International Journal of Cardiology, 2016, 209, 20-21.	1.7	4
42	Intravascular haemolysis after transcatheter aortic valve implantation with self-expandable prosthesis: incidence, severity, and impact on long-term mortality. European Heart Journal Supplements, 2020, 22, F44-F50.	0.1	3
43	Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe. European Heart Journal Supplements, 2022, 24, B3-B9.	0.1	3
44	Platelet-derived chemokines, PF-4 and RANTES, are significantly increased in hemodynamically significant degenerative aortic stenosis. International Journal of Cardiology, 2011, 152, 273-275.	1.7	2
45	Use of Amplatzer occluders for treatment of aorto-pulmonary fistulas â€“ case and review of the literature. Expert Review of Medical Devices, 2017, 14, 845-847.	2.8	2
46	OUP accepted manuscript. European Heart Journal Supplements, 2022, 24, B36-B41.	0.1	2
47	Optical coherence tomography in STEMI with bioresorbable scaffold: possible cause of coronary flow impairment? A sub-study from the Prague 19 trial. Heart and Vessels, 2018, 33, 1282-1287.	1.2	1
48	The Bioresorbable Stent in Perspectiveâ€"How Much of an Advance is It?. Interventional Cardiology Review, 2011, 9, 23.	1.6	1
49	Transcatheter aortic valve implantation - what do we know in 2020. Vnitrni Lekarstvi, 2020, 66, 282-286.	0.2	1
50	Predictors allowing early discharge after interventional treatment of acute coronary syndrome patients. European Heart Journal Supplements, 2022, 24, B10-B15.	0.1	1
51	OUP accepted manuscript. European Heart Journal Supplements, 2022, 24, B23-B27.	0.1	1
52	TCT-404 ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-year results from a propensity score matched comparison. Journal of the American College of Cardiology, 2016, 68, B164.	2.8	0
53	Manual aspiration thrombectomy devices use in coronary interventions in 2016. Expert Review of Medical Devices, 2016, 13, 243-251.	2.8	0
54	OCT findings of radiotherapy-induced coronary artery disease: A â€œtwo-hit combined hypothesisâ€• Journal of Cardiology Cases, 2020, 22, 149-151.	0.5	0

#	Article	IF	Citations
55	What antithrombotic treatment is required in a patient after TAVI in the year 2021?. Intervencni A Akutni Kardiologie, 2021, 20, 111-115.	0.0	0
56	Spatially Organized Structure of Coronary Thrombus in Acute Myocardial Infarction. Blood, 2016, 128, 716-716.	1.4	0
57	Bioresorbable vascular scaffold - good idea worth further effort. Intervencni A Akutni Kardiologie, 2017, 16, 106-108.	0.0	0